乳腺癌组织中Cyclin D1、MYBL2表达及其对预后影响的研究-东南大学学报医学版

乳腺癌组织中Cyclin D1、MYBL2表达及其对预后影响的研究

单位：1. 昆山市第二人民医院乳腺外科, 江苏昆山 215300;
2. 昆山市第二人民医院病理科, 江苏昆山 215300

分类号：R737.9

出版年·卷·期（页码）：2023·42·第三期（411-418）

摘要：

目的: 检测乳腺癌组织中细胞周期蛋白D1(Cyclin D1)、Myb相关蛋白B (MYBL2)表达,并分析其对预后的影响。方法: 回顾性选取2015年1月至2019年12月本院确诊为乳腺癌且进行初次乳腺癌手术切除患者的乳腺癌石蜡组织标本185例,取癌组织和癌旁正常组织采用免疫组化二步法测定Cyclin D1、MYBL2表达并比较,分析癌组织中二者的相关性以及蛋白表达与临床病理特征的关系,进行Kaplan-Meier生存分析,Cox回归分析预后不良的影响因素。结果: 癌组织Cyclin D1、MYBL2阳性表达率、二者同时阳性表达率均高于癌旁正常组织(P＜0.05);癌组织Cyclin D1、MYBL2表达呈正相关(P＜0.001);双侧患病、Ⅲ~Ⅳ期、未/低分化患者的癌组织Cyclin D1、MYBL2阳性表达率、二者同时阳性表达率均分别高于单侧患病、Ⅰ~Ⅱ期、中/高分化患者(P＜0.05);患者随访期间死亡率为20.00%,且癌组织Cyclin D1、MYBL2阳性表达患者无病生存时间(DFS)和总生存时间(OS)均短于阴性表达患者(P＜0.05),二者同时阳性表达患者的DFS和OS均短于二者非同时阳性表达患者(P＜0.05);癌组织Cyclin D1、MYBL2阳性表达者死亡率均高于Cyclin D1、MYBL2阴性表达者(P＜0.05),二者同时阳性表达患者死亡率高于二者非同时阳性表达者(P＜0.05);随访期间患者的预后不良发生率为60.54%,双侧患病、Ⅲ~Ⅳ期、未/低分化、三阴性乳腺癌、癌组织Cyclin D1和MYBL2阳性表达均为患者预后不良的危险因素(P＜0.05)。结论: 乳腺癌组织Cyclin D1、MYBL2蛋白阳性表达率、二者同时阳性表达率高,与临床病理特征及预后均有关。

Objective: To detect the expression of Cyclin D1 and Myb related protein B(MYBL2) in breast cancer tissues, and analyze their effects on prognosis. Methods: 185 paraffin tissue samples of breast cancer patients diagnosed in our hospital from January 2015 to December 2019 who underwent primary breast cancer surgery were retrospectively selected, and the expressions of Cyclin D1 and MYBL2 in cancer tissues and normal tissues adjacent to cancer were detected by immunohistochemical two-step method, and the correlation analysis was done. The relationship between protein expressions and clinical pathological characteristics was analyzed, and Kaplan-Meier survival analysis was used. Cox regression analysis was used to explore the influencing factors of poor prognosis. Results: The positive expression rates of Cyclin D1, MYBL2 and Cyclin D1+MYBL2 in cancer tissues were higher than those of normal adjacent tissues(P<0.05). The expressions of Cyclin D1 and MYBL2 in cancer tissues were positively correlated(P<0.001). The positive expression rates of Cyclin D1, MYBL2 and Cyclin D1+MYBL2 in cancer tissues of patients with bilateral disease, stage Ⅲ-Ⅳ and undifferentiated/poorly differentiated patients were higher than those of patients with unilateral disease, stage Ⅰ-Ⅱ and medium/well differentiated patients(P<0.05). The mortality rate during follow-up was 20.00%, and the disease-free survival time(DFS) and total survival time(OS) of patients with positive expressions of Cyclin D1, MYBL2 and Cyclin D1+MYBL2 in cancer tissues were respectively shorter than those of negative expressions and non-simultaneous expressions(P<0.05). The mortality of patients with positive expressions of Cyclin D1, MYBL2 and Cyclin D1+MYBL2 in cancer tissues were respectively higher than those of negative expressions and non-simultaneous expressions(P<0.05). During the following-up period, the incidence of poor prognosis was 60.54%. Cyclin D1 and MYBL2 positive expressions, bilateral disease, stage Ⅲ-Ⅳ, undifferentiated, triple negative breast cancer were risk factors for poor prognosis(P<0.05). Conclusion: The positive expression rates of Cyclin D1, MYBL2 and Cyclin D1+MYBL2 in breast cancer tissues are high, which are related to the clinicopathological characteristics and prognosis.

参考文献：

[1] 汤志英,万芳.乳腺癌发病流行病学影响因素调查及疗效分析[J].中国妇幼保健, 2021,36(10):2349-2353.
[2] CAO W,CHEN H D,YU Y W,et al.Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020[J].Chin Med J(Engl),2021,134(7):783-791.
[3] MOSELE F,STEFANOVSKA B,LUSQUE A,et al.Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer[J].Ann Oncol, 2020,31(3):377-386.
[4] YU J,JI G,SHI W,et al.RBM5 acts as tumor suppressor in medulloblastoma through regulating Wnt/β-catenin signaling[J].Eur Neurol,2020,83(3):242-250.
[5] HOU X,ZHANG Y,HAN S,et al.A novel DNA methylation 10-CpG prognostic signature of disease-free survival reveal that MYBL2 is associated with high risk in prostate cancer[J].Expert Rev Anticancer Ther,2020,20(12):1107-1119.
[6] 侯燕,涂健,杨天宇,等.MYBL2在前列腺癌组织中的表达及其临床意义[J].临床肿瘤学杂志,2022,27(7):590-594.
[7] LANE W O,THOMAS S M,BLITZBLAU R C,et al.Surgical resection of the primary tumor in women with de novo stage IV breast cancer: contemporary practice patterns and survival analysis[J].Ann Surg,2019,269(3):537-544.
[8] 张贺龙,刘文超.临床肿瘤学[M].西安:第四军医大学出版社, 2016:148-150.
[9] 陈杰.病理诊断免疫组化手册[M].北京:中国协和医科大学出版社, 2014:105-110.
[10] SANG K,YI T,HUANG X,et al.MiR-370-5p inhibits the progression of breast cancer via targeting LUC7L3[J].J Recept Signal Transduct Res,2021,41(5):442-450.
[11] LU N,ZHANG M,LU L,et al.Insulin-induced gene 2 expression is associated with breast cancer metastasis[J].Am J Pathol,2021,191(2):385-395.
[12] ZHANG X,SHI G,WU X,et al.Gypensapogenin H from hydrolyzate of total Gynostemma pentaphyllum saponins induces apoptosis in human breast carcinoma cells[J].Nat Prod Res,2020,34(11):1642-1646.
[13] 李玮玮,朱莹.数据挖掘分析MYB家族在乳腺癌中的表达及其预后评估价值[J].癌变·畸变·突变,2020,32(6):414-422.
[14] AL-KHAFAJI K,TASKIN TOK T.Amygdalin as multi-target anticancer drug against targets of cell division cycle: double docking and molecular dynamics simulation[J].J Biomol Struct Dyn,2021,39(6):1965-1974.
[15] 刘润奇,叶建森,徐天鸣,等.乳腺癌Ki-67和CyclinD1在预测及评估新辅助化疗疗效中的价值[J].西部医学,2022,34(5):753-756,760.
[16] 张鸿,李伟,毛智军,等.MYBL2在胃癌组织中的表达水平及其与患者预后、免疫细胞浸润的关系[J].临床医学研究与实践,2021,6(21):1-4.
[17] 孔令慧,王金花,郭志娟,等.cyclin D1与PD-L1在不同分子亚型浸润性乳腺癌中的表达及相关性分析[J].癌症进展,2019,17(19):2306-2308,2313.
[18] MAGBANUA M J M,SWIGART L B,WU H T,et al.Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival[J].Ann Oncol,2021,32(2):229-239.
[19] SLAMON D J,NEVEN P,CHIA S,et al.Overall survival with ribociclib plus fulvestrant in advanced breast cancer[J].N Engl J Med,2020,382(6):514-524.
[20] 赵春艳,胡先华,张人丹,等.烯醇化酶mRNA表达在乳腺癌患者中的预后判断价值[J].重庆医学,2020,49(9):1510-1514.
[21] 陈茂山,李芳芳,杨宏伟,等.基于SEER数据库分析142 007例乳腺癌诊断时婚姻状态与预后的关系[J].重庆医科大学学报,2020,45(11):1567-1572.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录